Pulmonary arterial hypertension (PAH) treatment is evolving, incorporating several pathway-specific approaches. Current therapies target endothelin receptors, the nitric oxide-cGMP pathway (using PDE5 inhibitors and sGC stimulators), the prostacyclin pathway, and activin signaling. These treatments aim to dilate pulmonary vessels and modify disease progression. Combination therapies have generally proven more effective than single-agent approaches, allowing for strategic combinations that optimize patient outcomes.

Sotatercept marks a significant advancement as the first activin signaling inhibitor. This fusion protein binds to activin A and B, along with other growth differentiation factors. This mechanism potentially reverses the remodeling of pulmonary vasculature by inducing apoptosis in proliferative cells obstructing the vessels.While reverse remodeling has been observed in animal models, sotatercept offers the first potential for such therapy in human PAH patients.

riociguat,which stimulates soluble guanylate cyclase and targets the nitric oxide pathway,is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension (CTEPH). In CTEPH, Riociguat can be used for patients with inoperable distal clots or in conjunction with balloon pulmonary angioplasty.For PAH patients, “riociguat is typically considered for intermediate-risk patients not achieving low-risk status, often as a substitution for PDE5 inhibitors in treatment algorithms.”

riociguat is typically considered for intermediate-risk patients not achieving low-risk status, frequently enough as a substitution for PDE5 inhibitors.

Understanding PAH Therapies

The treatment of pulmonary arterial hypertension involves targeting specific pathways to improve blood flow and reduce vascular remodeling. two notable drugs, Sotatercept and Riociguat, represent innovative approaches in this field.